Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
Humphreys, P.G., Anderson, N.A., Bamborough, P., Baxter, A., Chung, C.W., Cookson, R., Craggs, P.D., Dalton, T., Fournier, J.C.L., Gordon, L.J., Gray, H.F., Gray, M.W., Gregory, R., Hirst, D.J., Jamieson, C., Jones, K.L., Kessedjian, H., Lugo, D., McGonagle, G., Patel, V.K., Patten, C., Poole, D.L., Prinjha, R.K., Ramirez-Molina, C., Rioja, I., Seal, G., Stafford, K.A.J., Shah, R.R., Tape, D., Theodoulou, N.H., Tomlinson, L., Ukuser, S., Wall, I.D., Wellaway, N., White, G.(2022) J Med Chem 65: 15174-15207
- PubMed: 36378954 
- DOI: 10.1021/acs.jmedchem.2c01102
- Primary Citation of Related Structures:  
8B5G, 8B5H, 8B5I, 8B5J - PubMed Abstract: 
The bromodomain and extra terminal (BET) family of proteins are an integral part of human epigenome regulation, the dysregulation of which is implicated in multiple oncology and inflammatory diseases. Disrupting the BET family bromodomain acetyl-lysine (KAc) histone protein-protein interaction with small-molecule KAc mimetics has proven to be a disease-relevant mechanism of action, and multiple molecules are currently undergoing oncology clinical trials ...